| Record Information |
|---|
| Version | 5.0 |
|---|
| Status | Expected but not Quantified |
|---|
| Creation Date | 2012-09-06 15:16:49 UTC |
|---|
| Update Date | 2022-03-07 02:51:37 UTC |
|---|
| HMDB ID | HMDB0014445 |
|---|
| Secondary Accession Numbers | |
|---|
| Metabolite Identification |
|---|
| Common Name | Tenofovir |
|---|
| Description | Tenofovir is only found in individuals that have used or taken this drug. Tenofovir, marketed by Gilead Sciences under the trade name Viread®, belongs to a class of antiretroviral drugs known as nucleotide analogue reverse transcriptase inhibitors (nRTIs), which block reverse transcriptase, an enzyme crucial to viral production in HIV-infected people. [Wikipedia ]Tenofovir inhibits the activity of HIV reverse transcriptase by competing with the natural substrate deoxyadenosine 5’-triphosphate and, after incorporation into DNA, by DNA chain termination. Specifically, the drugs are analogues of the naturally occurring deoxynucleotides needed to synthesize the viral DNA and they compete with the natural deoxynucleotides for incorporation into the growing viral DNA chain. However, unlike the natural deoxynucleotides substrates, NRTIs and NtRTIs (nucleoside/tide reverse transcriptase inhibitors) lack a 3'-hydroxyl group on the deoxyribose moiety. As a result, following incorporation of an NRTI or an NtRTI, the next incoming deoxynucleotide cannot form the next 5'-3' phosphodiester bond needed to extend the DNA chain. Thus, when an NRTI or NtRTI is incorporated, viral DNA synthesis is halted, a process known as chain termination. All NRTIs and NtRTIs are classified as competitive substrate inhibitors. |
|---|
| Structure | C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1 |
|---|
| Synonyms | | Value | Source |
|---|
| (R)-PMPA | ChEBI | | Anh. tenofovir | ChEBI | | Anhydrous tenofovir | ChEBI | | Tenofovir (anh.) | ChEBI | | D,L-Tenofovir | HMDB | | PMPA | HMDB | | TDF | HMDB | | Tenofovir disoproxil | HMDB | | Tenofovir disoproxil fumarate | HMDB | | (R)-9-(2-Phosphonylmethoxypropyl)adenine | HMDB | | Fumarate, tenofovir disoproxil | HMDB | | 9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098 | HMDB | | 9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer | HMDB | | 9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer | HMDB | | 9-(2-Phosphonylmethoxypropyl)adenine | HMDB | | 9-(2-Phosphonomethoxypropyl)adenine | HMDB | | 9-PMPA (tenofovir) | HMDB | | Disoproxil fumarate, tenofovir | HMDB | | Disoproxil, tenofovir | HMDB | | Viread | HMDB |
|
|---|
| Chemical Formula | C9H14N5O4P |
|---|
| Average Molecular Weight | 287.2123 |
|---|
| Monoisotopic Molecular Weight | 287.078340473 |
|---|
| IUPAC Name | ({[(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy}methyl)phosphonic acid |
|---|
| Traditional Name | tenofovir |
|---|
| CAS Registry Number | 147127-20-6 |
|---|
| SMILES | C[C@H](CN1C=NC2=C1N=CN=C2N)OCP(O)(O)=O |
|---|
| InChI Identifier | InChI=1S/C9H14N5O4P/c1-6(18-5-19(15,16)17)2-14-4-13-7-8(10)11-3-12-9(7)14/h3-4,6H,2,5H2,1H3,(H2,10,11,12)(H2,15,16,17)/t6-/m1/s1 |
|---|
| InChI Key | SGOIRFVFHAKUTI-ZCFIWIBFSA-N |
|---|
| Chemical Taxonomy |
|---|
| Description | Belongs to the class of organic compounds known as 6-aminopurines. These are purines that carry an amino group at position 6. Purine is a bicyclic aromatic compound made up of a pyrimidine ring fused to an imidazole ring. |
|---|
| Kingdom | Organic compounds |
|---|
| Super Class | Organoheterocyclic compounds |
|---|
| Class | Imidazopyrimidines |
|---|
| Sub Class | Purines and purine derivatives |
|---|
| Direct Parent | 6-aminopurines |
|---|
| Alternative Parents | |
|---|
| Substituents | - 6-aminopurine
- Aminopyrimidine
- N-substituted imidazole
- Pyrimidine
- Imidolactam
- Azole
- Imidazole
- Organophosphonic acid
- Organophosphonic acid derivative
- Heteroaromatic compound
- Azacycle
- Organophosphorus compound
- Organooxygen compound
- Organonitrogen compound
- Organic oxygen compound
- Organopnictogen compound
- Amine
- Primary amine
- Organic oxide
- Hydrocarbon derivative
- Organic nitrogen compound
- Aromatic heteropolycyclic compound
|
|---|
| Molecular Framework | Aromatic heteropolycyclic compounds |
|---|
| External Descriptors | |
|---|
| Ontology |
|---|
| Physiological effect | Not Available |
|---|
| Disposition | |
|---|
| Process | |
|---|
| Role | Not Available |
|---|
| Physical Properties |
|---|
| State | Solid |
|---|
| Experimental Molecular Properties | | Property | Value | Reference |
|---|
| Melting Point | 276 - 280 °C | Not Available | | Boiling Point | Not Available | Not Available | | Water Solubility | 1.87 g/L | Not Available | | LogP | -1.6 | Not Available |
|
|---|
| Experimental Chromatographic Properties | Not Available |
|---|
| Predicted Molecular Properties | |
|---|
| Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Retention Times Underivatized| Chromatographic Method | Retention Time | Reference |
|---|
| Measured using a Waters Acquity ultraperformance liquid chromatography (UPLC) ethylene-bridged hybrid (BEH) C18 column (100 mm × 2.1 mm; 1.7 μmparticle diameter). Predicted by Afia on May 17, 2022. Predicted by Afia on May 17, 2022. | 2.24 minutes | 32390414 | | Predicted by Siyang on May 30, 2022 | 9.101 minutes | 33406817 | | Predicted by Siyang using ReTip algorithm on June 8, 2022 | 8.08 minutes | 32390414 | | AjsUoB = Accucore 150 Amide HILIC with 10mM Ammonium Formate, 0.1% Formic Acid | 265.0 seconds | 40023050 | | Fem_Long = Waters ACQUITY UPLC HSS T3 C18 with Water:MeOH and 0.1% Formic Acid | 940.3 seconds | 40023050 | | Fem_Lipids = Ascentis Express C18 with (60:40 water:ACN):(90:10 IPA:ACN) and 10mM NH4COOH + 0.1% Formic Acid | 221.3 seconds | 40023050 | | Life_Old = Waters ACQUITY UPLC BEH C18 with Water:(20:80 acetone:ACN) and 0.1% Formic Acid | 64.6 seconds | 40023050 | | Life_New = RP Waters ACQUITY UPLC HSS T3 C18 with Water:(30:70 MeOH:ACN) and 0.1% Formic Acid | 148.5 seconds | 40023050 | | RIKEN = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 54.8 seconds | 40023050 | | Eawag_XBridgeC18 = XBridge C18 3.5u 2.1x50 mm with Water:MeOH and 0.1% Formic Acid | 324.6 seconds | 40023050 | | BfG_NTS_RP1 =Agilent Zorbax Eclipse Plus C18 (2.1 mm x 150 mm, 3.5 um) with Water:ACN and 0.1% Formic Acid | 268.2 seconds | 40023050 | | HILIC_BDD_2 = Merck SeQuant ZIC-HILIC with ACN(0.1% formic acid):water(16 mM ammonium formate) | 540.8 seconds | 40023050 | | UniToyama_Atlantis = RP Waters Atlantis T3 (2.1 x 150 mm, 5 um) with ACN:Water and 0.1% Formic Acid | 577.1 seconds | 40023050 | | BDD_C18 = Hypersil Gold 1.9µm C18 with Water:ACN and 0.1% Formic Acid | 90.0 seconds | 40023050 | | UFZ_Phenomenex = Kinetex Core-Shell C18 2.6 um, 3.0 x 100 mm, Phenomenex with Water:MeOH and 0.1% Formic Acid | 620.2 seconds | 40023050 | | SNU_RIKEN_POS = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 159.0 seconds | 40023050 | | RPMMFDA = Waters ACQUITY UPLC BEH C18 with Water:ACN and 0.1% Formic Acid | 162.1 seconds | 40023050 | | MTBLS87 = Merck SeQuant ZIC-pHILIC column with ACN:Water and :ammonium carbonate | 500.7 seconds | 40023050 | | KI_GIAR_zic_HILIC_pH2_7 = Merck SeQuant ZIC-HILIC with ACN:Water and 0.1% FA | 417.6 seconds | 40023050 | | Meister zic-pHILIC pH9.3 = Merck SeQuant ZIC-pHILIC column with ACN:Water 5mM NH4Ac pH9.3 and 5mM ammonium acetate in water | 114.2 seconds | 40023050 |
Predicted Kovats Retention IndicesUnderivatizedDerivatized| Derivative Name / Structure | SMILES | Kovats RI Value | Column Type | Reference |
|---|
| Tenofovir,1TMS,isomer #1 | C[C@H](CN1C=NC2=C(N)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C | 2661.2 | Semi standard non polar | 33892256 | | Tenofovir,1TMS,isomer #1 | C[C@H](CN1C=NC2=C(N)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C | 2594.0 | Standard non polar | 33892256 | | Tenofovir,1TMS,isomer #1 | C[C@H](CN1C=NC2=C(N)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C | 4381.0 | Standard polar | 33892256 | | Tenofovir,1TMS,isomer #2 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C)N=CN=C21)OCP(=O)(O)O | 2691.8 | Semi standard non polar | 33892256 | | Tenofovir,1TMS,isomer #2 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C)N=CN=C21)OCP(=O)(O)O | 2668.2 | Standard non polar | 33892256 | | Tenofovir,1TMS,isomer #2 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C)N=CN=C21)OCP(=O)(O)O | 4713.9 | Standard polar | 33892256 | | Tenofovir,2TMS,isomer #1 | C[C@H](CN1C=NC2=C(N)N=CN=C21)OCP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 2612.8 | Semi standard non polar | 33892256 | | Tenofovir,2TMS,isomer #1 | C[C@H](CN1C=NC2=C(N)N=CN=C21)OCP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 2629.8 | Standard non polar | 33892256 | | Tenofovir,2TMS,isomer #1 | C[C@H](CN1C=NC2=C(N)N=CN=C21)OCP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 3995.3 | Standard polar | 33892256 | | Tenofovir,2TMS,isomer #2 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C | 2659.4 | Semi standard non polar | 33892256 | | Tenofovir,2TMS,isomer #2 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C | 2710.2 | Standard non polar | 33892256 | | Tenofovir,2TMS,isomer #2 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C | 4023.4 | Standard polar | 33892256 | | Tenofovir,2TMS,isomer #3 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C21)OCP(=O)(O)O | 2633.7 | Semi standard non polar | 33892256 | | Tenofovir,2TMS,isomer #3 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C21)OCP(=O)(O)O | 2823.5 | Standard non polar | 33892256 | | Tenofovir,2TMS,isomer #3 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C21)OCP(=O)(O)O | 4184.1 | Standard polar | 33892256 | | Tenofovir,3TMS,isomer #1 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C)N=CN=C21)OCP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 2660.9 | Semi standard non polar | 33892256 | | Tenofovir,3TMS,isomer #1 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C)N=CN=C21)OCP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 2718.1 | Standard non polar | 33892256 | | Tenofovir,3TMS,isomer #1 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C)N=CN=C21)OCP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 3623.6 | Standard polar | 33892256 | | Tenofovir,3TMS,isomer #2 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C | 2648.6 | Semi standard non polar | 33892256 | | Tenofovir,3TMS,isomer #2 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C | 2776.2 | Standard non polar | 33892256 | | Tenofovir,3TMS,isomer #2 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C | 3587.0 | Standard polar | 33892256 | | Tenofovir,4TMS,isomer #1 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C21)OCP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 2682.6 | Semi standard non polar | 33892256 | | Tenofovir,4TMS,isomer #1 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C21)OCP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 2782.3 | Standard non polar | 33892256 | | Tenofovir,4TMS,isomer #1 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C)[Si](C)(C)C)N=CN=C21)OCP(=O)(O[Si](C)(C)C)O[Si](C)(C)C | 3210.2 | Standard polar | 33892256 | | Tenofovir,1TBDMS,isomer #1 | C[C@H](CN1C=NC2=C(N)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C(C)(C)C | 2901.6 | Semi standard non polar | 33892256 | | Tenofovir,1TBDMS,isomer #1 | C[C@H](CN1C=NC2=C(N)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C(C)(C)C | 2795.0 | Standard non polar | 33892256 | | Tenofovir,1TBDMS,isomer #1 | C[C@H](CN1C=NC2=C(N)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C(C)(C)C | 4427.7 | Standard polar | 33892256 | | Tenofovir,1TBDMS,isomer #2 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O)O | 2893.9 | Semi standard non polar | 33892256 | | Tenofovir,1TBDMS,isomer #2 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O)O | 2906.6 | Standard non polar | 33892256 | | Tenofovir,1TBDMS,isomer #2 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O)O | 4648.1 | Standard polar | 33892256 | | Tenofovir,2TBDMS,isomer #1 | C[C@H](CN1C=NC2=C(N)N=CN=C21)OCP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3077.0 | Semi standard non polar | 33892256 | | Tenofovir,2TBDMS,isomer #1 | C[C@H](CN1C=NC2=C(N)N=CN=C21)OCP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3002.2 | Standard non polar | 33892256 | | Tenofovir,2TBDMS,isomer #1 | C[C@H](CN1C=NC2=C(N)N=CN=C21)OCP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 4087.1 | Standard polar | 33892256 | | Tenofovir,2TBDMS,isomer #2 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C(C)(C)C | 3069.3 | Semi standard non polar | 33892256 | | Tenofovir,2TBDMS,isomer #2 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C(C)(C)C | 3108.0 | Standard non polar | 33892256 | | Tenofovir,2TBDMS,isomer #2 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C(C)(C)C | 4105.4 | Standard polar | 33892256 | | Tenofovir,2TBDMS,isomer #3 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O)O | 3067.8 | Semi standard non polar | 33892256 | | Tenofovir,2TBDMS,isomer #3 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O)O | 3222.2 | Standard non polar | 33892256 | | Tenofovir,2TBDMS,isomer #3 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O)O | 4140.1 | Standard polar | 33892256 | | Tenofovir,3TBDMS,isomer #1 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3251.8 | Semi standard non polar | 33892256 | | Tenofovir,3TBDMS,isomer #1 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3237.1 | Standard non polar | 33892256 | | Tenofovir,3TBDMS,isomer #1 | C[C@H](CN1C=NC2=C(N[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3829.2 | Standard polar | 33892256 | | Tenofovir,3TBDMS,isomer #2 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C(C)(C)C | 3230.6 | Semi standard non polar | 33892256 | | Tenofovir,3TBDMS,isomer #2 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C(C)(C)C | 3319.7 | Standard non polar | 33892256 | | Tenofovir,3TBDMS,isomer #2 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O)O[Si](C)(C)C(C)(C)C | 3708.6 | Standard polar | 33892256 | | Tenofovir,4TBDMS,isomer #1 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3403.5 | Semi standard non polar | 33892256 | | Tenofovir,4TBDMS,isomer #1 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3407.4 | Standard non polar | 33892256 | | Tenofovir,4TBDMS,isomer #1 | C[C@H](CN1C=NC2=C(N([Si](C)(C)C(C)(C)C)[Si](C)(C)C(C)(C)C)N=CN=C21)OCP(=O)(O[Si](C)(C)C(C)(C)C)O[Si](C)(C)C(C)(C)C | 3491.6 | Standard polar | 33892256 |
|
|---|
| GC-MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Predicted GC-MS | Predicted GC-MS Spectrum - Tenofovir GC-MS (Non-derivatized) - 70eV, Positive | splash10-0002-2920000000-93fa3e16e2deed5b1e92 | 2017-09-01 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Tenofovir GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum | | Predicted GC-MS | Predicted GC-MS Spectrum - Tenofovir GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS Spectra| Spectrum Type | Description | Splash Key | Deposition Date | Source | View |
|---|
| Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir LC-ESI-QFT , negative-QTOF | splash10-000i-0290000000-3e1938b3d02b375e35df | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir LC-ESI-QFT , negative-QTOF | splash10-001r-1930000000-d365f36771addeb5b51c | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir LC-ESI-QFT , negative-QTOF | splash10-001i-2900000000-c8f91e6bb9d4588f055d | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir LC-ESI-QFT , negative-QTOF | splash10-001i-2900000000-099f967e8f8229f1fb82 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir LC-ESI-QFT , negative-QTOF | splash10-001i-3900000000-521761795a56429a8f51 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir LC-ESI-QFT , negative-QTOF | splash10-06si-5900000000-b88fc7e5619f18889624 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir LC-ESI-QFT , positive-QTOF | splash10-000i-0090000000-e85e6b9ea88e6c214687 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir LC-ESI-QFT , positive-QTOF | splash10-000i-0190000000-405fbe60309faffed10c | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir LC-ESI-QFT , positive-QTOF | splash10-004r-0950000000-d7cec4ba580879c76061 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir LC-ESI-QFT , positive-QTOF | splash10-004i-0910000000-f2abf612e945d8c69371 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir LC-ESI-QFT , positive-QTOF | splash10-056r-1900000000-c48435c099065334ef3e | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir LC-ESI-QFT , positive-QTOF | splash10-0570-1900000000-7b90db7cba32420df6d1 | 2017-09-14 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir 75V, Positive-QTOF | splash10-056r-0900000000-de4511ad1a86f8a69306 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir 90V, Positive-QTOF | splash10-0570-1900000000-735f5903582c7fb18e93 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir 15V, Positive-QTOF | splash10-000i-0090000000-a439fd9f7f987e4575fa | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir 15V, Negative-QTOF | splash10-000i-0290000000-6b581f541a52be20d9bb | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir 30V, Negative-QTOF | splash10-001r-1930000000-ebfded6e5a124700a539 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir 30V, Positive-QTOF | splash10-000i-0190000000-7587229ffd658c035ccc | 2021-09-20 | HMDB team, MONA | View Spectrum | | Experimental LC-MS/MS | LC-MS/MS Spectrum - Tenofovir 60V, Negative-QTOF | splash10-001i-2900000000-fc948e8fa5f1eff04475 | 2021-09-20 | HMDB team, MONA | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tenofovir 10V, Positive-QTOF | splash10-002r-0980000000-52e67b818d6f67ebe46b | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tenofovir 20V, Positive-QTOF | splash10-0040-6910000000-fa7c104ef806824be3de | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tenofovir 40V, Positive-QTOF | splash10-000i-2900000000-514c8cf39cc5d2610f23 | 2016-06-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tenofovir 10V, Negative-QTOF | splash10-000i-1290000000-cfa0589d123306000d96 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tenofovir 20V, Negative-QTOF | splash10-001i-2910000000-a76d01fa8fb2fbb25203 | 2016-08-03 | Wishart Lab | View Spectrum | | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Tenofovir 40V, Negative-QTOF | splash10-053r-4900000000-5eb36b143c3108e10d0c | 2016-08-03 | Wishart Lab | View Spectrum |
NMR Spectra| Spectrum Type | Description | Deposition Date | Source | View |
|---|
| Predicted 1D NMR | 1H NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 100 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 1000 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 200 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 300 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 400 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 500 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 600 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 700 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 800 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 1H NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum | | Predicted 1D NMR | 13C NMR Spectrum (1D, 900 MHz, D2O, predicted) | 2021-09-29 | Wishart Lab | View Spectrum |
|
|---|